Nefazodone Treatment of Comorbid Alcohol Dependence and Major Depression

Alcoholism: Clinical and Experimental Research

Volumn 28, Issue 3, 2004, Pages 433-440

  Hernandez Avila, Carlos A ^a   Modesto Lowe, Vania ^a   Feinn, Richard ^a   Kranzler, Henry R ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Alcohol Dependence; Alcoholism; Clinical Trial; Depression; Nefazodone

Indexed keywords

NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR DEPRESSION; MALE; MOOD; NAUSEA; NEUROPSYCHIATRY; PRIORITY JOURNAL; PSYCHOTHERAPY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; VISUAL IMPAIRMENT; VOMITING;

ADULT; ALCOHOLISM; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DUAL (PSYCHIATRY); DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; TRIAZOLES;

EID: 1642355865     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ALC.0000118313.63897.EE     Document Type: Article

References (47)

1. Adamson J, Burdick J (1973) Sleep of dry alcoholics. Arch Gen Psychiatry 28:146-149.
2. Allen RP, Faillace LA, Wagman A (1971) Recovery time for alcoholics after prolonged alcohol intoxication. Johns Hopkins Med J 128:158-164.
3. Armitage R, Yonkers K, Cole D, Rush AJ (1997) A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol 17:161-168.
4. Bristol-Myers Squibb Co. (2003) Letter concerning black box warning for Serzone. February 10.
5. Brown ES, Bobadilla L, Nejtek VA, Perantie D, Dhillon H, Frol A (2003) Open-label nefazodone in patients with a major depressive episode and alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry 27: 681-685.
6. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193-213.
7. Carvajal GP, Garcia D, Sanchez SA, Velasco MA, Rueda D, Lucena MI (2002) Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 63:135-137.
8. Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates, Hillsdale, NJ.
9. Cyr M, Brown CS (1996) Nefazodone: its place among antidepressants. Ann Pharmacother 30:1006-1012.
10. Davis R, Whittington R, Bryson HM (1997) Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53:608-636.
11. Gillin JC, Rapaport M, Erman MK, Winokur A, Albala BJ (1997) A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 58:185-192.
12. Gillin JC, Smith TL, Irwin M, Butters N, Demodena A, Schuckit M (1994) Increased pressure for rapid eye movement sleep at time of hospital admission predicts relapse in nondepressed patients with primary alcoholism at 3-month follow-up. Arch Gen Psychiatry 51:189-197.
13. Gillin JC, Smith TL, Irwin M, Kripke DF, Brown S, Schuckit M (1990) Short REM latency in primary alcoholic patients with secondary depression. Am J Psychiatry 147:106-109.
14. Gorelick DA (1989) Serotonin uptake blockers and the treatment of alcoholism. Recent Dev Alcohol 7:267-281.
15. Graeff FG, Viana MB, Mora PO (1997) Dual role of 5-HT in defense and anxiety. Neurosci Biobehav Rev 21:791-799.
16. Greene DS, Barbhaiya RH (1997) Clinical pharmacokinetics of nefazone. Clin Pharmacokinet 33:260-275.
17. Gross MM, Hastey JM (1976) Sleep disturbances in alcoholism, in Alcoholism: Interdisciplinary Approaches to an Enduring Problem (Tarter RE, Sugarman A eds), pp 257-309. Addison-Wesley, Reading, MA.
18. Hamilton M (1959) The assessment of anxiety states by rating. Br J Psychol 32:50-55.
19. Hesselbrock MH, Meyer RE, Keener JJ (1985) Psychopathology in hospitalized alcoholics. Arch Gen Psychiatry 42:1050-1055.
20. Khantzian E (1985) The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 142:1259-1264.
21. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn MJ (1994) Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry 51:720-731.
22. Kranzler HR, Mason B, Modesto-Lowe V (1998) Prevalence, diagnosis, and treatment of comorbid mood disorders and alcoholism, in Dual Diagnosis and Treatment (Kranzler HR, Rounsaville B eds), pp 107-136. Marcel Dekker, New York.
23. Kranzler HR, Modesto-Lowe V, Van Kirk J (2000) Naltrexone vs. nefazodone for treatment of alcohol dependence: a placebo-controlled trial. Neuropsychopharmacology 22:493-503.
24. Levine J, Schooler NR (1986) SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22: 343-381.
25. Levy AD, Van de Kar LD (1992) Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants. Life Sci 51:83-94.
26. Littell R, Milliken G, Stroup W, Wolfinger R (1996) SAS System for Mixed Models. SAS Institute, Cary, NC.
27. Markou A, Kosten TR, Koob GF (1998) Neurobiological similarities in depression and drug dependence. A self-medication hypothesis. Neuropsychopharmacology 18:135-174.
28. McGrath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, Quitkin FM (1996) Imipramine treatment of alcoholics with primary depression. Arch Gen Psychiatry 53:232-240.
29. Miller WR, Tonigan JS, Longabaugh R (1995) The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse (Project MATCH Monograph Series) (NIH Publication No. 95-3911). Vol 4. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, Rockville, MD.
30. Mossberg D, Liljeberg P, Borg S (1985) Clinical conditions in alcoholics during long term abstinence: a descriptive longitudinal treatment study. Alcohol 2:551-553.
31. Nunes EV, McGrath PJ (1995) Treating anxiety in patients with alcoholism. J Clin Psychiatry (Suppl 2) 56:3-9.
32. Olausson P, Ericson M, Petersson A, Kosowski A, Soderpalm B, Engel JA (1998) Nefazodone attenuates the behavioral and neurochemical effects of ethanol. Alcohol 15:77-86.
33. Powell BJ, Penick EC, Othmer E, Bingham SF, Rice AS (1982) Prevalence of additional psychiatric syndromes among male alcoholics. J Clin Psychiatry 43:404-407.
34. Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminara JA, Marcus RN (1996) The safety profile of nefazodone. J Clin Psychiatry (Suppl 2) 57:31-38.
35. Roy A, Virkkunen M, Linnoila M (1990) Serotonin in suicide, violence, and alcoholism, in Serotonin in Major Psychiatric Disorders (Coccaro EF, Murphy DL eds), pp 187-208. American Psychiatric Press, Washington, DC.
36. Roy-Byrne P, Pages KP, Russo JE, Blume AW, Jaffe C, Kingsley E, Cowley DS, Ries RK (2000) A double-blind placebo-controlled trial of nefazodone in the treatment of major depression in alcohol dependent patients. J Clin Psychopharmacol 20:129-136.
37. Schuckit M (1983) Alcoholic patients with secondary depression. Am J Psychiatry 140:711-714.
38. Sharpley AL, Williamson DJ, Attenburrow MEJ, Pearson G, Sargent P, Cowen PJ (1996) The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology 126:50-54.
39. Shoaf SE, Linnoila M (1991) Interaction of ethanol and smoking on the pharmacokinetics and pharmacodynamics of psychotropic medications. Psychopharmacol Bull 27:577-594.
40. Skoloda TE, Alterman AL, Gottheil E (1979) Sleep quality reported by drinking and non-drinking alcoholics, in Addiction Research and Treatment: Converging Trends (Gottheil EL ed), pp 102-112. Pergamon Press, Elmsford, NY.
41. Sobell LC, Sobell MB (1992) Timeline followback: a technique for assessing self-reported ethanol consumption, in Measuring Alcohol Consumption: Psychosocial and Biological Methods (Allen J, Litten RZ eds), pp 41-72. Humana Press, Totowa, NJ.
42. Spielberger C, Gorsuch A, Lushene R (1970) The State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA.
43. Spitzer RL, Williams JBW, Gibbon M, First MB (1992) The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale and description. Arch Gen Psychiatry 49:624-629.
44. Stewart DE (2002) Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 47:375-377.
45. Stockmeier CA (1997) Neurobiology of serotonin in depression and suicide. Ann NY Acad Sci 836:220-232.
46. Thase ME, Greenhouse JB, Frank E, Reynolds CF III, Pilkonis PA, Hurley K, Grochocinski V, Kupfer DJ (1997) Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 54:1009-1015.
47. Vaillant GE, Clark W, Cyrus C, Milofsky ES, Kopp J, Wulsin VW, Mogielnicki NP (1983) Prospective study of alcoholism treatment. Eight-year follow-up. Am J Med 75:455-463.